Regeneron Pharmaceuticals (REGN) FY2015 results: revenue $4.1 billion, up 45.5% on the year
Regeneron Pharmaceuticals, Inc. (REGN) reported revenue of $4.1 billion for fiscal 2015, the year ended 31 December 2015, up 45.5% on the year before. Net income was $636 million, up 88.1%, and diluted earnings per share $5.52. The figures are the company's own, from the 10-K it filed with the SEC on 11 February 2016.
Revenue
$4.1 billion
+45.5% on the year
FY2008FY2015
Operating margin
30.5%
29.2% a year earlier
FY2008FY2015
Net income
$636 million
+88.1% on the year
FY2008FY2015
Diluted EPS
$5.52
+85.2% on the year
FY2008FY2015
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2015
FY2014
FY2013
On the year
Last 8 years
Revenue
4,104
2,820
2,105
+45.5%
Cost of revenue
242
129
118
+87.3%
Gross profit
3,862
2,691
1,987
+43.5%
Gross margin
94.1%
95.4%
94.4%
Research and development
1,621
1,271
860
+27.5%
Selling, general and administrative
839
519
346
+61.5%
Operating income
1,252
824
743
+51.9%
Operating margin
30.5%
29.2%
35.3%
Interest expense
14.2
37.4
46.4
-61.9%
Pre-tax income
1,225
761
696
+60.9%
Income tax
589
423
283
+39.2%
Effective tax rate
48.1%
55.6%
40.6%
Net income
636
338
414
+88.1%
Net margin
15.5%
12.0%
19.7%
Diluted EPS
$5.52
$2.98
$3.72
+85.2%
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2015
FY2014
FY2013
On the year
Last 8 years
Operating cash flow
1,331
752
589
+76.9%
Capital expenditure
678
333
156
+103.6%
Free cash flow
653
419
432
+55.7%
Free cash flow margin
15.9%
14.9%
20.5%
Cash from investing
-908
-421
-355
Cash from financing
-263
-219
72.2
Depreciation and amortisation
74.9
52.7
41.2
+42.2%
Share-based compensation
459
322
215
+42.7%
Diluted shares, weighted
115m
113m
111m
+1.6%
Balance sheet
$ million
FY2015
FY2014
FY2013
On the year
Last 8 years
Shareholders' equity
3,655
2,550
1,965
+43.3%
Debt
0.0
147
320
Other liabilities
1,954
1,141
666
+71.3%
Total liabilities and equity
5,609
3,838
2,951
+46.2%
Fixed assets
1,594
974
527
+63.6%
Investments
868
712
548
+22.0%
Cash and equivalents
809
649
536
+24.7%
Receivables
1,152
739
787
+55.9%
Inventory
239
129
70.4
+85.1%
Other assets
947
634
483
+49.2%
Total assets
5,609
3,838
2,951
+46.2%
10-K for the year ended 31 December 2015, filed 11 February 2016: the filing.